Galderma Group AG Registered Shares GDERF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Skincare Specialist Galderma to Buy ZO Skin Health for $1.5 Billion — Update
-
Galderma to Buy ZO Skin Health for $1.5 Billion
-
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
-
Galderma Raises 2026 Sales Guidance on Strong Growth
-
Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. — Update
-
Galderma Shares Fall After Bid to Launch Botox Rival in U.S. Hits FDA Setback
-
Galderma Application for Product to Rival Botox Turned Down Again by FDA
-
Galderma Shares Gain After Sales Increase, Confidence on Outlook
Trading Information
- Previous Close Price
- $197.80
- Day Range
- $201.78–216.70
- 52-Week Range
- $167.00–248.46
- Bid/Ask
- $206.10 / $221.30
- Shares Outstanding
- 233.19M
- Market Cap
- $50.83B
- Volume/Avg
- 66 / 1,122
Key Statistics
- Price/Earnings (Normalized)
- 50.09
- Price/Sales
- 7.71
- Dividend Yield (Trailing)
- 0.21%
- Dividend Yield (Forward)
- 0.21%
- Dividend Payment Schedule
- Apr
- Total Yield
- 0.91%
Company Profile
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 7,600
- Website
- https://www.galderma.com
Competitors
Valuation
|
Metric
|
GDERF
|
BEI
|
OR
|
|---|---|---|---|
Price/Earnings (Normalized) | 50.09 | 13.64 | 31.07 |
Price/Book Value | 5.50 | 1.93 | 6.09 |
Price/Sales | 7.71 | 1.81 | 4.57 |
Price/Cash Flow | 38.20 | 14.83 | 23.66 |
Price/Earnings
GDERF
BEI
OR
Financial Strength
|
Metric
|
GDERF
|
BEI
|
OR
|
|---|---|---|---|
Quick Ratio | 0.93 | 1.50 | 0.58 |
Current Ratio | 1.24 | 2.00 | 0.97 |
Interest Coverage | 6.84 | 42.97 | 19.89 |
Quick Ratio
GDERF
BEI
OR
Profitability
|
Metric
|
GDERF
|
BEI
|
OR
|
|---|---|---|---|
Return on Assets (Normalized) | 7.31% | 7.60% | 11.46% |
Return on Equity (Normalized) | 12.07% | 11.37% | 20.96% |
Return on Invested Capital (Normalized) | 10.17% | 10.80% | 15.09% |
Return on Assets
GDERF
BEI
OR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|xgNy>#Sb | LOCK|@C%F | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|>M^SDv% | LOCK|#>NBq | $49B | |||
| Haleon PLC ADR
HLN
| LOCK|WYT<<@ | LOCK|rz$ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|<fH#>yRC | LOCK|jk | $32B | |||
| Viatris Inc
VTRS
| LOCK|h&@px@ | LOCK|>GS | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|B? | LOCK|T^N | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|<SC?#p | LOCK|KXd | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|k?h!jgz | LOCK|%<V | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|C@@S?d< | LOCK|yD?G | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|n@&Gf# | LOCK|^<V | $2B |
United States